Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age19-70
SponsorShanghai Pulmonary Hospital, Shanghai, China
About this trial
Randomized phase II trial aims to compare surgery with or without adjuvant chemotherapy in treating patients who are pathologically diagnosed as stage I lung adenocarcinoma with micropapillary component no less than 20%.
Eligibility criteria
Qualifiers
Completely resected Stage I NSCLC as defined by the International Staging System
Pathologically diagnosed Stage I micropapillary predominant lung adenocarcinoma
Patients must be randomized within 4 weeks from the date of surgery
No prior chemotherapy or radiation for non-small cell lung cancer
Disqualifiers
Do not meet the inclusion criteria
There is evidence of distant metastases
Suffered from other malignancies in five years
Within the past January subjects received other drug trials
Trial design
Treatments tested in this trial
- cis Platinum/Carboplatin, Pemetrexed Disodium
- Undergo surgery
Treatment groups
460 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov